Dr. Daniel G. Bruetman, MD

Dr. Bruetman practices at Northwestern Medical Group in Chicago, Illinois.

Dr. Bruetman's NPI, 1972583417, was assigned on January 19, 2006. Dr. Bruetman holds Indiana license 01054353A.

Dr. Bruetman's primary practice is Northwestern Medical Group, at 675 N Saint Clair St Ste 19-100 Suite 19-100, Chicago, IL 60611. The practice phone is (312) 664-3278.

Dr. Bruetman's primary practice is Northwestern Medical Group in Chicago, Illinois. Dr. Bruetman is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Bruetman to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bruetman practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Bruetman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Bruetman is licensed in Indiana.

CMS data shows 259 Medicare services from Dr. Bruetman across 5 procedure codes in 2024, for 58 Medicare patients. Medicare paid $18,058 for them. Every service was in an office.

CMS counts 58 Medicare patients who saw Dr. Bruetman in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 38% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bruetman's median patient age at 66, with 71% women.

In 2024, Dr. Bruetman wrote 152 Medicare Part D claims for 31 patients. 70% of them were for generic drugs. CMS names the drug for 72 of them, across 5 drugs with 11 or more claims each, at $285,086 in total drug cost. In 2023, CMS named 79 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Bruetman for performance year 2024, reported as part of a group. Dr. Bruetman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bruetman as offering telehealth.

Dmand AI links Dr. Bruetman to 6 clinical trials, 4 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Non-Small-Cell Lung.

CMS Open Payments shows 112 general payments to Dr. Bruetman from 31 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 47% of the total. Varian Medical Systems, Inc. paid the most, $3,382.